IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00316784

Recruitment Status : Completed

First Posted : April 21, 2006

Last Update Posted : March 20, 2009

Sponsor:

Information provided by:

IDEA AG

Study Description

Brief Summary:

The study objective is the eluciation of the dose-response function in efficacy (and possibly safety) in order to determine an optimal dose with respect to efficacy and safety. The study is designed with three dose levels and one placebo control.

Condition or disease	Intervention/treatment	Phase
Osteoarthritis; Knee	Drug: IDEA-033 (and rescue medication)	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	704 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee
Study Start Date :	July 2005
Study Completion Date :	May 2006

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Osteoarthritis

MedlinePlus related topics: Osteoarthritis

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC Pain subscale (primary)
patient global assessment of response to therapy measured on a 5-point Likert Scale at week 12 or end of study measurements (co-primary)
change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC function subscale (co-primary)

Secondary Outcome Measures :

Change from baseline at week 12 (or end of study measurements) for Physician's Global Assessment of OA and for observed function (TUG)
Mean number of rescue medication taken per day while in the study
Number of withdrawals and time to discontinuation of the study due to lack of efficacy
Time to onset (in days) of pain relief and time to onset of new flares during treatment
Change from baseline on the vitality subscale of the SF-36 health survey and the EURO QoL

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

clinical diagnosis of OA in at least one knee for a minimum of 6 months
aged 18-75 years old
eligible subjects must have used an oral or rectal NSAID on at least three days per week during the three months before screening or on at least 25 of the 30 days before screening, but be dissatisfied with the current NSAID treatment
at baseline visit WOMAC pain subscale at least 40 mm, and at least 15 mm greater than at the screening visit in the index knee
radiographic evidence consistent with OA criteria of grade 2 or 3 according to Kellgren & Lawrence in the index knee. Radiographs mus have been taken during the 6 months before baseline.
American College of Rheumatology (ACR) functional class I, II or III

Exclusion Criteria:

intraarticular injections or arthroscopy of the index knee within 3 months prior to screening, or planned during the study
history, physical examinations or radiographs suggestive of other rhematic diseases
known hypersensitivity or contraindication to ketoprofen; NSAID idiosyncrasy
history of peptic ulcers
severe liver or gastro-intestinal disease within the last 6 months
injections or change in oral treatment regimen of glucosamine, chondroitin sulfate, hyaluronic acid, shark cartilage, or vitamin E within 3 months prior to screening
oral or parenteral corticosteroids within 3 months prior to screening
analgesic therapy for chronic or recurrent pain conditions for indications other than OA
immunosuppressants within 3 months prior to screening

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00316784

Sponsors and Collaborators

IDEA AG

Investigators


Principal Investigator:	Gerold Stucki, Prof, MD	department of physical medicine and rehabilitation of universtity Munich

More Information


ClinicalTrials.gov Identifier:	NCT00316784 History of Changes
Other Study ID Numbers:	CL-033-III-02/E
First Posted:	April 21, 2006 Key Record Dates
Last Update Posted:	March 20, 2009
Last Verified:	March 2009

Keywords provided by IDEA AG:


osteoarthritis; knee; IDEA-033

Additional relevant MeSH terms:


Osteoarthritis Osteoarthritis, Knee Arthritis	Joint Diseases Musculoskeletal Diseases Rheumatic Diseases

To Top